Status:

RECRUITING

Radiofrequency Ablation for BIII Thyroid Nodules

Lead Sponsor:

Columbia University

Conditions:

Indeterminate Bethesda III Thyroid Nodules

Eligibility:

All Genders

18+ years

Brief Summary

The purpose of this observational chart review study is to evaluate the efficacy and safety of Radiofrequency Ablation (RFA) for treatment of indeterminate thyroid nodules before and after RFA procedu...

Detailed Description

In the United States, there is an estimated 10% lifetime probability for developing a thyroid nodule. Up to 15% of these nodules will prove to be malignant. The incidence of thyroid cancer is increas...

Eligibility Criteria

Inclusion

  • Indeterminate Bethesda III nodules that have been molecularly profiled benign with either Afirma Genomic Sequencing Classifier (GSC) or ThyroSeq v3 tests

Exclusion

  • cardiac arrthymias
  • pregnancy

Key Trial Info

Start Date :

August 1 2020

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

August 1 2027

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT05189808

Start Date

August 1 2020

End Date

August 1 2027

Last Update

May 28 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Columbia University

New York, New York, United States, 10032

Radiofrequency Ablation for BIII Thyroid Nodules | DecenTrialz